Scribe Therapeutics, Inc.
corporate_fare Company Profile
Scribe Therapeutics, Inc. (NASDAQ:SCTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for SCTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for SCTX spans 8-K, 10-Q, SCHEDULE 13D, 4.
Recent high-impact activity:
- Scribe Posts Q3 Loss of $9.9M; $174.2M Cash Funds Operations Into 1H 2029
- Scribe 10-Q Reveals Going Concern Was Only Resolved by July IPO; Reverse Split and Lilly Note Conversion Detailed
- Scribe Therapeutics Reports Q2 2026 Results: STX-1150 Enters Clinic, Cash Runway to 2029
- Avoro Capital Lifts Scribe Therapeutics Stake to 16.4%, Adding Open-Market Buys and Lock-Up Details
- Eli Lilly Discloses 7.3% Strategic Stake in Scribe Therapeutics Post-IPO
Short Interest & Short Volume
4.01 days to coverFINRA reported short interest of 1,671,740 shares in SCTX as of the October 30, 2026 settlement, a 49.5% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On November 19, 2026, 76.0% of SCTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SCTX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-24.
IPO Terms Finalized · Concurrent Private Placement
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →